Observational studyMedicine2025
Ultrasound-guided attenuation parameter for hepatic steatosis quantification in psoriasis: a retrospective cohort study: Quantitatively evaluate of hepatic steatosis.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ultrasound-guided attenuation parameter (UGAP), a validated hepatic steatosis quantification modality, demonstrates superior diagnostic accuracy in metabolic dysfunction-associated fatty liver disease (MAFLD). This study aimed to evaluate the occurrence and characteristics of hepatic steatosis in patients with psoriasis by UGAP. Psoriatic inpatients (March-October 2023) at Binzhou Medical University Hospital were enrolled, excluding those with secondary chronic liver disease etiologies. The control group, recruited from nonpsoriasis physical examiners, were matched for gender, age, and body mass index (BMI). The UGAP of all participants were measured. A total of 86 participants were included in this study, among whom 61 were patients with psoriasis and 25 were in the control group. The UGAP values of psoriasis patients were significantly higher than those of the nonpsoriasis group (0.65 vs 0.60, P = .01). Psoriasis severity index (PASI)-stratified analysis revealed severe psoriasis patients demonstrated prolonged disease duration and elevated UGAP versus mild-to-moderate counterparts (0.69 vs 0.63, P = .03). Spearman correlation analysis showed that in the psoriasis population, the correlation coefficient between the PASI scores and the UGAP values was 0.42 (P < .001). Age and UGAP values were significant predictors of a higher PASI score independent of gender, age at onset, duration of psoriasis and BMI. A bidirectional connection exists between hepatic steatosis and psoriasis progression. UGAP, as a promising quantitative assessment tool for hepatic steatosis, demonstrates significant correlations with psoriasis severity indices. This modality sensitively reflects the gradation of hepatic lipid deposition in psoriatic patients and exhibits predictive value for disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.